Vical Halts Development of HSV-2 Vaccine after Phase II Failure

The HSV-2 vaccine missed its primary endpoint in the Phase II study of annualized lesion recurrence rate

GE Healthcare, Swedish Government Open an Innovation Center in Uppsala

Testa Center focuses on advancing manufacturing capabilities and the commercialization of new technologies in life sciences, aligning with Sweden's goals of strengthening its capacity for innovation and thus its economic competitiveness.

Lilly, Dicerna Launch $3.7B+ RNAi Collaboration

Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10...

Breast Cancer Immunotherapy Delivered without Side Effects

While cancer immunotherapy is one of the most exciting new research areas due to the potential it holds for treating tumors that have been...

Novel RNA-based Vaccine Provides Protection Against Malaria

Researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites use to evade the immune system

FDA Approves First Smallpox-Indicated Treatment, SIGA’s TPOXX

With the approval, SIGA said, it is entitled to a $41 million payment under its a $472M contract with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), which joined SIGA in developing the treatment.

Biosimilars: 10 Drugs to Watch

The world’s largest two markets for prescription medicines remain a study in contrasts: The European Medicines Agency authorizes 11 biosimilar drugs for market in the nations comprising the EU. Meanwhile in the U.S., the FDA continues to ponder draft guidances for how the agency will evaluate biosimilars.

Anti-Obesity “Biochemical Cigarette” Exploits Body’s Responses to Cold and Smoking

Researchers in Europe and Australia have developed an anti-obesity “chemical cigarette” that exploits the body’s natural responses to both cold exposure and smoking. The...

LGLS Licenses Novavax’ VLP Technology to Develop Flu Vaccines for South...

Firm will build VLP vaccine manufacturing plant and will also develop flu vaccines for other emerging markets.

False-Negative Test Results Put Severe Influenza Patients at Serious Risk

Negative rapid test results may delay antiviral therapy in patients with severe influenza

Recently Featured

Stay Connected

Scroll Up